Akero Therapeutics Reports Strong Financial Growth
Akero Therapeutics, Inc. (NASDAQ: AKRO), a clinical-stage company focused on innovative treatments for serious metabolic diseases, recently shared its impressive financial results for the second quarter of 2025, revealing significant advancements in their clinical programs.
Phase 2b SYMMETRY Clinical Trial Excites Industry
During the second quarter, Akero showcased promising results from their Phase 2b SYMMETRY trial, which evaluated their lead product candidate, efruxifermin (EFX). This trial reported statistically significant reversal of compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH).
Publication in Renowned Journal
The findings from the 96-week SYMMETRY study were published in the prestigious New England Journal of Medicine. This recognition highlights the potential of EFX as a revolutionary therapy in treating advanced MASH.
Presentation Highlights from Recent Congress
At the recent EASL Congress 2025, Akero delivered three compelling presentations focusing on the efficacy of EFX in reversing cirrhosis in specific patient subgroups, notably those suffering from cryptogenic cirrhosis and type 2 diabetes. This underlines the therapy's promise not just for early-stage but also advanced liver disease patients.
Insights from Phase 2b HARMONY Study
Additionally, new analyses from the Phase 2b HARMONY study were revealed, indicating consistent improvement in fibrosis among patients with pre-cirrhotic MASH. EFX demonstrated superior antifibrotic responses as compared to placebo, utilizing both traditional pathology scoring and advanced AI analysis.
Financial Overview: Continued Growth and Investment
As of June 30, 2025, Akero reported cash reserves and marketable securities totaling $1,086.2 million. This robust financial position enables the company to continue funding its studies and anticipated objectives well into 2028, anticipating further growth as they progress towards Phase 3 trials.
Detailed Financial Insights
Akero reported research and development expenses of $69.3 million for the second quarter, representing an increase from $55.3 million in the same period the previous year. This rise is attributed to enhanced clinical trial activities and an expanded workforce.
Understanding MASH and Its Implications
MASH is a serious form of liver disease that has grown significantly, now affecting an estimated 17 million individuals in the United States alone. This condition, characterized by fat accumulation in the liver, can lead to severe complications including cirrhosis, liver failure, and cancer. With an alarming 20% of MASH patients expected to progress to cirrhosis, the urgency for effective therapies is paramount.
About Efruxifermin (EFX)
Efruxifermin is Akero's lead product candidate designed to target and improve metabolic dysfunctions associated with MASH. Its promising profile is supported by numerous Phase 2 studies that suggest its potential to reverse fibrosis and improve liver health effectively.
Actively Engaging Community and Stakeholders
Akero continues to prioritize stakeholder engagement, ensuring transparency and proactive communication through regular updates of trial progress and financial health. This strategy positions them well for sustained investor confidence and partnership opportunities.
Contact Information
If you're interested in learning more about Akero Therapeutics, feel free to reach out to their Investor Relations at:
Christina Tartaglia
332.322.7430
christina.tartaglia@precisonaq.com
Media inquiries can be directed to:
Peg Rusconi
617.910.6217
peg.rusconi@deerfieldgroup.com
Frequently Asked Questions
What is the significance of the SYMMETRY trial results?
The SYMMETRY trial results show statistically significant improvements in reversing compensated cirrhosis, marking a potential breakthrough in MASH treatment.
How much cash does Akero Therapeutics currently have?
As of June 30, 2025, Akero holds approximately $1,086.2 million in cash and marketable securities.
What is MASH, and why is it a concern?
MASH is a growing liver disease affecting millions, leading to severe health issues including cirrhosis and liver cancer, necessitating effective treatment options.
What is Efruxifermin (EFX) used for?
EFX targets metabolic dysfunctions related to MASH, showing promise in reversing liver fibrosis and enhancing overall liver health.
When can we expect more results from Akero's trials?
Preliminary results from the first Phase 3 trial, SYNCHRONY, are anticipated in the first half of 2026.
